ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in various dosages. This launch expands the company's injectable portfolio and presence in the U.S. hospital market.
Glenmark Pharmaceuticals received U.S. FDA approval for its Fluticasone Propionate Nasal Spray. The product will be distributed in the U.S. market.
Glenmark Pharmaceuticals released its Business Responsibility & Sustainability Report for the financial year 2025-26. This filing adheres to SEBI's regulatory disclosure requirements.
Glenmark Pharmaceuticals Limited has issued the notice for its 48th Annual General Meeting, scheduled to be held on September 11, 2026, through video conferencing.
Glenmark Pharmaceuticals agreed to a $15.28 million settlement with Humana, Inc. to resolve antitrust litigation. This payment has been fully provided for in the company's financials.
Glenmark Pharmaceuticals Limited has allotted 23,863 equity shares following the exercise of options under its ESOP 2016 scheme. This allotment increases the company's paid-up capital to Rs. 28,22,24,672.